Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Nucleic Acid Pharma

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1788213

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1788213

Nucleic Acid Therapeutics CDMO

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Nucleic Acid Therapeutics CDMO Market to Reach US$39.5 Billion by 2030

The global market for Nucleic Acid Therapeutics CDMO estimated at US$16.6 Billion in the year 2024, is expected to reach US$39.5 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. RNA-based Therapies, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$28.3 Billion by the end of the analysis period. Growth in the Gene Therapies segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 14.6% CAGR

The Nucleic Acid Therapeutics CDMO market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.1 Billion by the year 2030 trailing a CAGR of 14.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.6% and 13.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.2% CAGR.

Global Nucleic Acid Therapeutics CDMO Market - Key Trends & Drivers Summarized

Why Are Nucleic Acid Therapeutics Reshaping the Role of CDMOs in the Biopharmaceutical Supply Chain?

Nucleic acid therapeutics-comprising modalities like antisense oligonucleotides (ASOs), small interfering RNA (siRNA), messenger RNA (mRNA), aptamers, and CRISPR-based gene editors-are driving a paradigm shift in the global pharmaceutical landscape. Their growing potential to treat previously intractable diseases, from rare genetic disorders to cancer and infectious diseases, is generating a massive wave of research and commercial interest. In this context, contract development and manufacturing organizations (CDMOs) have emerged as essential partners in the delivery pipeline. Unlike traditional biologics or small molecules, nucleic acid therapeutics require highly specialized capabilities in oligonucleotide synthesis, enzymatic production, lipid nanoparticle formulation, and sterile fill-finish processes. The complexity, customization, and regulatory rigor involved in developing and scaling these therapies have prompted biopharma innovators-especially small and mid-sized biotech firms-to increasingly outsource their manufacturing operations to experienced CDMOs. As clinical pipelines grow and diversify, CDMOs are assuming more strategic roles in process optimization, analytical method development, and cGMP manufacturing, often becoming long-term collaborators from preclinical stages to commercial launch. The success of mRNA-based COVID-19 vaccines has also validated the scalability and commercial viability of nucleic acid platforms, further accelerating demand for CDMOs with robust infrastructure, technical expertise, and regulatory track records in this space.

How Are Technological Capabilities and Infrastructure Investments Driving CDMO Differentiation?

With the nucleic acid therapeutics market maturing, CDMOs are undergoing a significant transformation in their service portfolios and technological capabilities to keep pace with evolving client demands. High-performance oligonucleotide synthesis platforms, automated purification systems, and next-generation analytical tools are now central to a CDMO’s competitive edge. In parallel, the industry is seeing massive investments in dedicated manufacturing suites for RNA and DNA therapeutics, modular cleanroom facilities, and high-throughput fill-finish lines capable of handling complex formulations such as lipid nanoparticle (LNP) encapsulated mRNA. Single-use bioreactor systems, closed processing units, and microfluidic technologies are being adopted to minimize contamination risks and optimize yields. Moreover, digital transformation is becoming a key enabler of efficiency, with CDMOs deploying electronic batch records, real-time monitoring systems, and data-driven process control to enhance quality assurance and reduce time-to-market. A critical area of differentiation lies in the ability to provide integrated end-to-end services-from process development and analytical characterization to scale-up and regulatory documentation. CDMOs that offer early-phase flexibility combined with late-stage scalability are increasingly preferred by biotech clients with accelerated development timelines and complex therapeutic profiles. Strategic acquisitions, partnerships, and geographic expansions are further shaping the competitive landscape, as players race to build specialized infrastructure capable of supporting a global pipeline of nucleic acid therapies.

How Are Regulatory Complexity and Market Dynamics Shaping the CDMO Opportunity Landscape?

As nucleic acid therapeutics transition from experimental platforms to mainstream treatment modalities, the regulatory environment surrounding their development and manufacturing is rapidly evolving. Agencies such as the FDA, EMA, and PMDA are introducing more specific guidelines for oligonucleotide synthesis, mRNA production, and LNP formulation, which places additional compliance burdens on CDMOs. Those capable of navigating this complexity with regulatory foresight and robust quality systems are increasingly favored by biopharma clients aiming to de-risk their development paths. Moreover, the trend toward accelerated approvals, fast-track designations, and orphan drug incentives has created compressed timelines, compelling sponsors to rely more heavily on CDMOs with proven track records in rapid scale-up and tech transfer. Simultaneously, global disparities in cold-chain logistics, GMP standards, and local regulatory expectations are pushing CDMOs to diversify their operations and establish regionally compliant hubs in North America, Europe, and Asia-Pacific. The competitive intensity in the nucleic acid CDMO space is also heightened by the entry of legacy biologics manufacturers and emerging players, leading to a surge in capacity building, talent acquisition, and specialization. Additionally, pricing pressures and cost-sensitive clients in the rare disease and personalized medicine sectors are prompting CDMOs to balance customization with manufacturing efficiency. These market dynamics are not only reshaping CDMO-client relationships but are also fostering the emergence of innovation-focused, quality-driven service models across the nucleic acid therapeutics value chain.

What’s Driving the Growth of the Nucleic Acid Therapeutics CDMO Market?

The growth in the nucleic acid therapeutics CDMO market is driven by several factors spanning technological innovation, evolving biopharma pipelines, changing regulatory landscapes, and increasing outsourcing trends. First, the rapid expansion of mRNA, siRNA, ASO, and gene-editing programs across biotech and pharmaceutical companies is creating sustained demand for specialized development and manufacturing expertise. Second, the technical and logistical complexity of producing nucleic acid-based drugs-especially those requiring lipid nanoparticles, cold-chain handling, and cGMP-grade purity-is pushing sponsors to engage with CDMOs that offer end-to-end capabilities. Third, the success of mRNA vaccines and the broader validation of nucleic acid platforms have attracted significant investment into the sector, enabling both established and emerging CDMOs to expand infrastructure and innovate in process technology. Fourth, the global push toward faster development timelines and regulatory acceleration is driving demand for CDMOs that can navigate complex compliance requirements while ensuring rapid scalability. Fifth, personalized medicine, rare disease treatments, and oncology pipelines increasingly rely on nucleic acid modalities, further boosting the need for flexible, agile manufacturing partners. In addition, rising outsourcing across the biopharma sector-particularly by small and virtual biotech firms with limited in-house capacity-is fueling continuous demand for CDMO collaboration. Together, these factors are shaping a robust, high-growth global market for CDMOs specializing in nucleic acid therapeutics, positioning them as critical enablers of the next wave of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Nucleic Acid Therapeutics CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (RNA-based Therapies, Gene Therapies); Service (Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services, Other Services); End-Use (Biotech Companies End-Use, Pharmaceutical Companies End-Use, Government & Academic Research Institutes End-Use); Application (Genetic Disorders, Rare Diseases, Infectious Diseases, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Bachem Holding AG
  • BioCina Pty Ltd.
  • BIOSPRING GmbH
  • Catalent, Inc.
  • Corden Pharma International
  • Curia Global, Inc.
  • Danaher Corporation (Aldevron)
  • Eurogentec
  • FUJIFILM Diosynth Biotechnologies
  • Integrated DNA Technologies, Inc.
  • KNC Laboratories Co., Ltd.
  • LGC Limited
  • Lonza Group Ltd
  • Merck KGaA
  • Nitto Denko Avecia Inc.
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP32383

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Nucleic Acid Therapeutics CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pipeline of RNA and DNA-Based Drugs Throws the Spotlight on CDMOs Specializing in Nucleic Acid Therapeutics
    • Increased Outsourcing by Emerging Biotechs Strengthens the Business Case for Full-Service Nucleic Acid CDMOs
    • Here's How mRNA Vaccine Success Has Expanded the Addressable Market Opportunity for Nucleic Acid Platforms
    • Growing Complexity of Nucleic Acid Manufacturing Spurs Demand for Specialized Facilities and Process Expertise
    • Advances in Lipid Nanoparticle (LNP) and Delivery Technologies Drive Adoption of CDMO Partnerships
    • Regulatory Acceleration for Orphan and Rare Disease Therapies Generates Demand for Agile Manufacturing Support
    • Personalized Medicine and Gene Editing Trends Propel Growth in Flexible, Small-Batch Nucleic Acid CDMO Services
    • End-to-End Service Integration and One-Stop Development Models Enhance CDMO Value Proposition for Biopharma Clients
    • Increased Focus on GMP Compliance and Quality Systems Strengthens CDMO Role in Commercial-Scale Manufacturing
    • Expansion of Global Clinical Trials and Decentralized R&D Drives Geographic Diversification of CDMO Operations
    • Digitalization and Process Automation in Nucleic Acid Manufacturing Boost Operational Efficiency and Transparency
    • Surging Demand for Plasmid DNA and Oligonucleotide APIs Fuels Infrastructure Investments Among CDMOs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nucleic Acid Therapeutics CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for RNA-based Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for RNA-based Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Gene Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Manufacturing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Manufacturing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Process Development & Optimization Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Process Development & Optimization Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Analytical & Quality Control Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Analytical & Quality Control Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Government & Academic Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Government & Academic Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • JAPAN
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • CHINA
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 54: China Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • EUROPE
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • FRANCE
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 72: France Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • GERMANY
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • ITALY
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 96: UK Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!